Asou N, Suzushima H, Hamasaki N, Goto J, Hidaka M, Akagi K, Kurisaki H, Sawatari T, Kawano F, Takatsuki K
Rinsho Ketsueki. 1989 Feb;30(2):169-74.
Sixteen adults with acute myelogenous leukemia (AML) in relapse or refractory to conventional therapy were treated with AB-Triple V therapy. This regimen consists of aclarubicin, behenoyl cytosine arabinoside, etoposide, vincristine, and vinblastine or vindesine. Patients who obtained complete remission (CR) were then given monthly three courses of AB-Triple V therapy, and further courses of AB-triple V therapy every three months. Eleven of the 16 patients entered CR, three were no response, and two died early after initial AB-Triple V therapy. Among 11 patients who achieved CR, 7 are alive and in CR during 1 to 13 months, one died of hepatic failure, and three patients died of infection in CR. Systemic arthralgia following the administration of vinblastine were frequently observed. These results indicate that this salvage therapy are useful relapsed or refractory AML. Therefore, the role of this combination chemotherapy as a part of the initial post-remission therapy needs to be evaluated.
16例复发或对传统治疗耐药的急性髓性白血病（AML）成人患者接受了AB-三联V疗法治疗。该方案由阿柔比星、山嵛酰阿糖胞苷、依托泊苷、长春新碱和长春碱或长春地辛组成。获得完全缓解（CR）的患者随后每月接受三个疗程的AB-三联V疗法，每三个月进一步接受AB-三联V疗法疗程。16例患者中有11例进入CR，3例无反应，2例在初始AB-三联V疗法后早期死亡。在11例实现CR的患者中，7例在1至13个月期间存活且处于CR状态，1例死于肝功能衰竭，3例在CR期间死于感染。经常观察到长春碱给药后出现全身性关节痛。这些结果表明，这种挽救疗法对复发或难治性AML有用。因此，需要评估这种联合化疗作为初始缓解后治疗一部分的作用。
